102.05
price up icon16.20%   14.23
after-market After Hours: 104.07 2.02 +1.98%
loading
Monopar Therapeutics Inc stock is traded at $102.05, with a volume of 89,000. It is up +16.20% in the last 24 hours and up +107.33% over the past month. Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$87.82
Open:
$90.75
24h Volume:
89,000
Relative Volume:
1.70
Market Cap:
$629.64M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-44.37
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+2.56%
1M Performance:
+107.33%
6M Performance:
+192.49%
1Y Performance:
+1,755%
1-Day Range:
Value
$90.01
$103.00
1-Week Range:
Value
$86.26
$103.00
52-Week Range:
Value
$4.50
$105.00

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name
Name
Monopar Therapeutics Inc
Name
Phone
(847) 388-0349
Name
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Name
Employee
16
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MNPR's Discussions on Twitter

Compare MNPR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MNPR
Monopar Therapeutics Inc
102.05 541.85M 0 -7.12M -6.82M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-09-25 Initiated BTIG Research Buy
Sep-03-25 Initiated Oppenheimer Outperform
Sep-03-25 Initiated Raymond James Strong Buy
Aug-26-25 Resumed H.C. Wainwright Buy
Jul-07-25 Initiated Cantor Fitzgerald Overweight
Jun-23-25 Initiated Chardan Capital Markets Buy
Mar-19-25 Resumed Piper Sandler Overweight
Jan-10-25 Initiated Piper Sandler Overweight
Oct-11-24 Initiated Rodman & Renshaw Buy
Jan-28-21 Initiated ROTH Capital Buy
View All

Monopar Therapeutics Inc Stock (MNPR) Latest News

pulisher
11:54 AM

Is Monopar Therapeutics Inc. stock safe for conservative investorsChart Signals & Smart Money Movement Tracker - newser.com

11:54 AM
pulisher
11:16 AM

Is Monopar Therapeutics Inc. forming a reversal patternPortfolio Gains Summary & Breakout Confirmation Alerts - newser.com

11:16 AM
pulisher
10:18 AM

Multi factor analysis applied to Monopar Therapeutics Inc.2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com

10:18 AM
pulisher
09:48 AM

Will Monopar Therapeutics Inc. stock recover faster than peersJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com

09:48 AM
pulisher
08:36 AM

MNPR: Barclays Initiates Coverage with Overweight Rating | MNPR Stock News - GuruFocus

08:36 AM
pulisher
08:25 AM

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

08:25 AM
pulisher
05:54 AM

Monopar Therapeutics initiated with an Overweight at Barclays - TipRanks

05:54 AM
pulisher
Oct 12, 2025

Real time social sentiment graph for Monopar Therapeutics Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Monopar Therapeutics (NASDAQ:MNPR) Raised to Strong-Buy at Jones Trading - Defense World

Oct 12, 2025
pulisher
Oct 11, 2025

Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 12.3%Here's What Happened - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Monopar Therapeutics (NASDAQ:MNPR) Upgraded to "Strong-Buy" at Jones Trading - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR) - Seeking Alpha

Oct 10, 2025
pulisher
Oct 10, 2025

Institutional scanner results for Monopar Therapeutics Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Monopar Therapeutics' (MNPR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential - TipRanks

Oct 10, 2025
pulisher
Oct 10, 2025

What analysts say about Monopar Therapeutics Inc stockProtective Put Strategies & Low Risk Investment Trading - earlytimes.in

Oct 10, 2025
pulisher
Oct 09, 2025

How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

Raymond James Maintains Monopar Therapeutics (MNPR) Strong Buy Recommendation - Nasdaq

Oct 06, 2025
pulisher
Oct 06, 2025

MNPR: Raymond James Raises Price Target to $142, Maintains Stron - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year HighTime to Buy? - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsWatch List & Fast Gaining Stock Strategy Reports - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Historical volatility pattern of Monopar Therapeutics Inc. visualizedTrade Entry Summary & Entry Point Strategy Guides - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Monopar Therapeutics Inc. (1IY0) stock beat Nasdaq index returnsTrade Risk Summary & Long-Term Safe Investment Ideas - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Risk adjusted return profile for Monopar Therapeutics Inc. analyzedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Watch List & Fast Entry Momentum Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Monopar Therapeutics Inc. (1IY0) stock overpriced at current multiplesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Using portfolio simulators with Monopar Therapeutics Inc. includedJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsGlobal Markets & Community Shared Stock Ideas - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Can volume confirm reversal in Monopar Therapeutics Inc.July 2025 Macro Moves & Reliable Price Breakout Signals - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Oppenheimer Maintains Monopar Therapeutics (MNPR) Outperform Recommendation - Nasdaq

Oct 02, 2025
pulisher
Oct 02, 2025

Oppenheimer Raises Price Target for Monopar Therapeutics (MNPR) - GuruFocus

Oct 02, 2025
pulisher
Oct 02, 2025

Oppenheimer Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $115 - 富途牛牛

Oct 02, 2025
pulisher
Oct 02, 2025

BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - 富途牛牛

Oct 02, 2025
pulisher
Oct 02, 2025

HC Wainwright Has Optimistic Outlook of MNPR FY2027 Earnings - Defense World

Oct 02, 2025

Monopar Therapeutics Inc Stock (MNPR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Monopar Therapeutics Inc Stock (MNPR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Tsuchimoto Kim R
Director
Jul 14 '25
Sale
40.00
8,904
356,171
11,486
STARR CHRISTOPHER M
Director
Jul 14 '25
Sale
40.00
16,800
672,020
5,173
Robinson Chandler
Chief Executive Officer
Jul 14 '25
Sale
40.00
16,800
672,020
73,472
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):